A Glowing Opportunity to Target YAP in Lung Fibrosis

Richard R Neubig^{1

2}

Affiliations

Editorial

Richard R Neubig. Am J Respir Cell Mol Biol. 2022 Jul.

. 2022 Jul;67(1):1-2.

doi: 10.1165/rcmb.2022-0082ED.

Richard R Neubig^{1

2}

No abstract available

Comment on

Screening for Inhibitors of YAP Nuclear Localization Identifies Aurora Kinase A as a Modulator of Lung Fibrosis.
Yang Y, Santos DM, Pantano L, Knipe R, Abe E, Logue A, Pronzati G, Black KE, Spinney JJ, Giacona F, Bieler M, Godbout C, Nicklin P, Wyatt D, Tager AM, Seither P, Herrmann FE, Medoff BD. Yang Y, et al. Am J Respir Cell Mol Biol. 2022 Jul;67(1):36-49. doi: 10.1165/rcmb.2021-0428OC. Am J Respir Cell Mol Biol. 2022. PMID: 35377835 Free PMC article.

1. Tschumperlin DJ, Liu F, Tager AM. Biomechanical regulation of mesenchymal cell function. Curr Opin Rheumatol . 2013;25:92–100. - PMC - PubMed
1. Haak AJ, Tsou PS, Amin MA, Ruth JH, Campbell P, Fox DA, et al. Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J Pharmacol Exp Ther . 2014;349:480–486. - PMC - PubMed
1. Liu F, Lagares D, Choi KM, Stopfer L, Marinković A, Vrbanac V, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol . 2015;308:L344–L357. - PMC - PubMed
1. Yang Y, Santos DM, Pantano L, Knipe R, Abe E, Logue A, et al. Screening for inhibitors of YAP nuclear localization identifies Aurora kinase A as a modulator of lung fibrosis. Am J Respir Cell Mol Biol . 2022 - PMC - PubMed
1. Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol . 2014;32:44–50. - PMC - PubMed